Plan now for a rotation away from riskier and volatile technology growth stocks and toward blue chips with more promise and ...

Sometimes you get these days where it feels like the market has returned to some semblance of what you’re used to when things ...

Biopharma giant Johnson & Johnson’s ($JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

The U.S. drug regulator said on Friday a unit of Johnson & Johnson issued a correction for certain lots of a part related to ...

In the first quarter, Kathleen S. Wright Associates Inc. slashed its stake in Johnson & Johnson by a hefty 21.1%, unloading 1 ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Los Angeles Capital Management LLC dramatically increased its Johnson & Johnson holdings by 213.6% in Q1, now owning ...

In this video, Sham Mailankody, MBBS, discusses results from a first-in-human study of JNJ-5322, a next-generation trispecific antibody for treatment of patients with relapsed or refractory multiple ...

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish ...

Johnson & Johnson MedTech (NYSE:JNJ) today announced a strategic co-promotion agreement with Pacira BioSciences.